Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race

Ashley E. Rosko, Kaitlyn Dvorak, Qiuhong Zhao, Electra Paskett, Samantha Jaglowski, James L. Fisher, Jessica Krok-Schoen, Francesca Cottini, Abdullah Khan, Srinivas Devarakonda, Naresh Bumma, Elvira Umyarova, Nidhi Sharma, Don M. Benson, Jr., Jesse Plascak

Blood (2022) 140 (Supplement 1): 5170–5171.

DOI: https://doi.org/10.1182/blood-2022-164653

Published: 2022

Journal Articles

The Co-Occurrence of 1q21+/1q23+ and t(4;14) Abnormalities with Specific Clone Size Is Predictive of Shorter Response to Transplant in Patients with Multiple Myeloma

Michael P. Ozga, Qiuhong Zhao, Naresh Bumma, Ashley E. Rosko, Abdullah Khan, Srinivas Devarakonda, Elvira Umyarova, Don M. Benson, Jr., Francesca Cottini

Blood (2022) 140 (Supplement 1): 9993–9994.

DOI: https://doi.org/10.1182/blood-2022-158693

Published: 2022

Journal Articles

T-Cell Senescence and Exhaustion Are Associated with Interval Progression of Multiple Myeloma before Autologous Hematopoietic Cell Transplant

Alicia Bao, Ruchi Kudalkar, Jose Rodriguez, Qiuhong Zhao, Nidhi Sharma, Naresh Bumma, Srinivas Devarakonda, Abdullah Khan, Ashley E. Rosko, Elvira Umyarova, Don M. Benson, Jr., Francesca Cottini

Blood (2022) 140 (Supplement 1): 7257–7258.

DOI: https://doi.org/10.1182/blood-2022-167226

Published: 2022

Journal Articles

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

Zachary Braunstein, Miguel Ruiz, Eric McLaughlin, Naresh Bumma, Don M Benson, Jr., Srinivas Devarakonda, Maria Chaudhry, Abdullah Khan, Francesca Cottini, John C. Reneau, Pierluigi Porcu, Anjali Mishra, Ashley E. Rosko, Jonathan E Brammer

Blood (2021) 138 (Supplement 1): 2449.

DOI: https://doi.org/10.1182/blood-2021-152556

Published: 2021

Journal Articles

Targeting the Mitotic Checkpoint in Myeloma with OSU-13, a Novel Mps1/Ttk Inhibitor

Larissa Valle Guilhen Longo, Betina McNeil-Laidley, Francesca Cottini, Tiffany Hughes, Gerald Hilinski, Elizabeth Merritt, Don M Benson, Jr.

Blood (2021) 138 (Supplement 1): 2660.

DOI: https://doi.org/10.1182/blood-2021-151124

Published: 2021

Journal Articles

Interval Progression Serves As a Predictor of Adverse Outcomes in Patients with Multiple Myeloma

Alicia Bao, Qiuhong Zhao, Nidhi Sharma, Naresh Bumma, Srinivas Devarakonda, Abdullah Khan, Ashley E. Rosko, Don M Benson, Jr., Francesca Cottini

Blood (2021) 138 (Supplement 1): 3940.

DOI: https://doi.org/10.1182/blood-2021-147835

Published: 2021

Journal Articles

Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma

Jordan Nunnelee, Muhammad Salman Faisal, Qiuhong Zhao, Francesca Cottini, Patrick Elder, Ashley E. Rosko, Maria Chaudhry, Abdullah Khan, Srinivas Devarakonda, Naresh Bumma, Don M Benson, Jr., Yvonne A. Efebera, Nidhi Sharma

Blood (2021) 138 (Supplement 1): 3796.

DOI: https://doi.org/10.1182/blood-2021-146698

Published: 2021

Journal Articles

CD56 Has a Critical Role in Regulating Multiple Myeloma Cell Growth and Response to Therapies

Francesca Cottini, Jose Rodriguez, Maxwell Birmingham, Tiffany Hughes, Nidhi Sharma, Gerard Lozanski, Bei Liu, Yiping Yang, Emanuele Cocucci, Don M Benson, Jr.

Blood (2021) 138 (Supplement 1): 889.

DOI: https://doi.org/10.1182/blood-2021-146370

Published: 2021

Journal Articles

Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Filiz Yucebay, PharmD, BCPS, BCOP, Ashleigh Keiter, MS, Qiuhong Zhao, MS, Alison Neal, Nita Williams, Nidhi Sharma, PhD, Francesca Cottini, MD, Maria Chaudhry, MD, Ashley Rosko, MD, Don M. Benson, Jr., MD PhD, Yvonne A. Efebera, MD MPH, Naresh Bumma, MD, Abdullah Khan, MBBS, MSc, Srinivas Devarakonda, MD

Blood (2020) 136 (Supplement 1): 1.

DOI: https://doi.org/10.1182/blood-2020-141105

Published: 2020

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

DOI: https://doi.org/10.1182/blood-2019-129128

Published: 2019

Journal Articles

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Jihad Aljabban, MMSc, BA, David Chen, BS, Francesca Cottini, MD, Saad Syed, BS, Nabeal Aljabban, BS, Sharjeel Syed, BS, Tiffany Hughes, PhD, David Feldman, BS, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2019) 134 (Supplement_1): 4395.

DOI: https://doi.org/10.1182/blood-2019-129699

Published: 2019

Journal Articles

Meta-Analysis Illustrates Role of Interferon-γ Signaling in Multiple Myeloma Pathogenesis

Jihad Aljabban, MMSc, BA, Nabeal Aljabban, BS, Mohamad Mukhtar, BS, Saad Syed, BS, Ross Wanner, BS, Francesca Cottini, MD, Tiffany Hughes, BS, PhD, Kareem Saleh, BS, Evan C Catton, Taylor Gonzalez, Maryam Panahiazar, PhD, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 4510.

DOI: https://doi.org/10.1182/blood-2018-99-112265

Published: 2018

Journal Articles

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

Taylor Gonzalez, Evan C Catton, Ashley E. Rosko, MD, Yvonne Efebera, MD, Maria Chaudhry, MD, Francesca Cottini, MD, Bethany L Mundy-Bosse, PhD, Tiffany Hughes, BS, PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 1933.

DOI: https://doi.org/10.1182/blood-2018-99-117465

Published: 2018

Journal Articles

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Teru Hideshima, Francesca Cottini, Yoshihisa Nozawa, Hyuk-Soo Seo, Hiroto Ohguchi, Mehmet K. Samur, Diana Cirstea, Naoya Mimura, Yoshikazu Iwasawa, Paul G. Richardson, Nikhil C. Munshi, Dharminder Chauhan, Walter Massefski, Teruhiro Utsugi, Sirano Dhe-Paganon, Kenneth C. Anderson

Blood (2017) 129 (10): 1308–1319.

DOI: https://doi.org/10.1182/blood-2016-09-738500

Published: 2017

Includes: Supplemental data

Journal Articles

G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma

Francesca Cottini, Douglas Sborov, Yu Kyoung Cho, Misty Lamprecht, Karen Tackett, Junan Li, Steven M. Devine, Ming Poi, Mitch A. Phelps, Craig C Hofmeister, MD MPH

Blood (2016) 128 (22): 5790.

DOI: https://doi.org/10.1182/blood.V128.22.5790.5790

Published: 2016

Journal Articles

Targeting Replicative Stress to Treat Hematological Disorders

Francesca Cottini, MD, Giovanni Tonon, MD PhD, Teru Hideshima, MD, PhD, Paul G. Richardson, MD, Kenneth C Anderson

Blood (2015) 126 (23): 2419.

DOI: https://doi.org/10.1182/blood.V126.23.2419.2419

Published: 2015

Journal Articles

Synthetic Lethal Approaches to Exploit Replicative Stress in Aggressive Myeloma

Francesca Cottini, Teru Hideshima, MDPhD, Rikio Suzuki, MDPhD, Paul G. Richardson, Kenneth C. Anderson, MD, Giovanni Tonon, MDPhD

Blood (2014) 124 (21): 173.

DOI: https://doi.org/10.1182/blood.V124.21.173.173

Published: 2014

Journal Articles

Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma

Francesca Cottini, Teru Hideshima, MDPhD, Sara Buhrlage, PhD, Nathanael S. Gray, PhD, Paul G. Richardson, Giovanni Tonon, MDPhD, Kenneth C Anderson, MD

Blood (2014) 124 (21): 645.

DOI: https://doi.org/10.1182/blood.V124.21.645.645

Published: 2014

Journal Articles

The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma

Francesca Cottini, MD, Teru Hideshima, MD, PhD, Giovanni Tonon, MD, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 3114.

DOI: https://doi.org/10.1182/blood.V122.21.3114.3114

Published: 2013

Journal Articles

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

Rikio Suzuki, MD, PhD, Teru Hideshima, MD, PhD, Shuichi Ohkubo, PhD, Naoya Mimura, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Shohei Kikuchi, MD, PhD, Diana D. Cirstea, Francesca Cottini, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Teruhiro Utsugi, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4429.

DOI: https://doi.org/10.1182/blood.V122.21.4429.4429

Published: 2013

NARROW

Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race

The Co-Occurrence of 1q21+/1q23+ and t(4;14) Abnormalities with Specific Clone Size Is Predictive of Shorter Response to Transplant in Patients with Multiple Myeloma

T-Cell Senescence and Exhaustion Are Associated with Interval Progression of Multiple Myeloma before Autologous Hematopoietic Cell Transplant

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

Targeting the Mitotic Checkpoint in Myeloma with OSU-13, a Novel Mps1/Ttk Inhibitor

Interval Progression Serves As a Predictor of Adverse Outcomes in Patients with Multiple Myeloma

Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma

CD56 Has a Critical Role in Regulating Multiple Myeloma Cell Growth and Response to Therapies

Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Meta-Analysis Illustrates Role of Interferon-γ Signaling in Multiple Myeloma Pathogenesis

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma

Targeting Replicative Stress to Treat Hematological Disorders

Synthetic Lethal Approaches to Exploit Replicative Stress in Aggressive Myeloma

Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma

The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only